Considering that the relevance of CD133 in malignancy of breast tumors is well established, our finding that PLC-β2 is involved in CD133-mediated invasiveness of cells derived from TNBC can contribute to better estimate the prognosis and more accurately identify therapeutic targets for TNBC, which remains a highly heterogeneous type of cancer and often an incurable illness. Here, PROM1 is linked to cancer.